How to buy Vertex Pharmaceuticals (VRTX) stocks

Vertex Pharmaceuticals is a biotechnology business based in the US. Vertex Pharmaceuticals shares (VRTX) are listed on the NASDAQ and all prices are listed in US Dollars.

Its last market close was $434.82 , which is a decrease of 12.84% over the previous week. Vertex Pharmaceuticals employs 6,100 staff and has a trailing 12-month revenue of around $11 billion.

Our top picks for where to buy Vertex Pharmaceuticals stock

Buy Vertex Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Vertex Pharmaceuticals stock price (NASDAQ: VRTX)

Use our graph to track the performance of VRTX stocks over time.

Vertex Pharmaceuticals stocks at a glance

• Key figures

Information last updated 2025-05-03.

Latest market close	$434.82
52-week range	$377.85 - $519.88
50-day moving average more info button	$492.05
200-day moving average more info button	$471.51
Wall St. target price	$500.32
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.10

Is it a good time to buy Vertex Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Is Vertex Pharmaceuticals stock undervalued or overvalued?

Valuing Vertex Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vertex Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Vertex Pharmaceuticals's PEG ratio

Vertex Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.374. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Vertex Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Vertex Pharmaceuticals's EBITDA

Vertex Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.8 billion.

The EBITDA is a measure of a Vertex Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Vertex Pharmaceuticals financials

Revenue TTM	$11 billion
Operating margin TTM	44.98%
Gross profit TTM	$6 billion
Return on assets TTM	12.68%
Return on equity TTM	-3.15%
Profit margin	-4.86%
Book value	$63.87
Market Capitalization more info button	$128.8 billion

TTM: trailing 12 months

Vertex Pharmaceuticals's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Vertex Pharmaceuticals.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Vertex Pharmaceuticals's total ESG risk score

Total ESG risk: 30.84

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Vertex Pharmaceuticals's overall score of 30.84 (as at 12/31/2018) is nothing to write home about – landing it in it in the 44th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Vertex Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Vertex Pharmaceuticals's environmental score

Environmental score: 5.65/100

Vertex Pharmaceuticals's environmental score of 5.65 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Vertex Pharmaceuticals's social score

Social score: 24.22/100

Vertex Pharmaceuticals's social score of 24.22 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Vertex Pharmaceuticals's governance score

Governance score: 12.46/100

Vertex Pharmaceuticals's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Vertex Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Vertex Pharmaceuticals's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Vertex Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Vertex Pharmaceuticals has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Vertex Pharmaceuticals Inc was last rated for ESG on: 2019-01-01.

Total ESG score	30.84
Total ESG percentile	44
Environmental score	5.65
Environmental score percentile	8
Social score	24.22
Social score percentile	8
Governance score	12.46
Governance score percentile	8
Level of controversy	2

Vertex Pharmaceuticals stock dividends

We're not expecting Vertex Pharmaceuticals to pay a dividend over the next 12 months.

Have Vertex Pharmaceuticals's stocks ever split?

Vertex Pharmaceuticals's stocks were split on a 2:1 basis on 23 August 2000 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Vertex Pharmaceuticals stocks – just the quantity. However, indirectly, the new 50% lower stock price could have impacted the market appetite for Vertex Pharmaceuticals stocks, which in turn could have impacted Vertex Pharmaceuticals's stock price.

Vertex Pharmaceuticals stock price volatility

Over the last 12 months, Vertex Pharmaceuticals's stocks have ranged in value from as little as $377.85 up to $519.88. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vertex Pharmaceuticals's is 0.506. This would suggest that Vertex Pharmaceuticals's stocks are less volatile than average (for this exchange).

Vertex Pharmaceuticals overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc.

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Vertex Pharmaceuticals is owned by insiders or institutions?
Currently 0.133% of Vertex Pharmaceuticals stocks are held by insiders and 95.828% by institutions. How many people work for Vertex Pharmaceuticals?
Latest data suggests 6,100 work at Vertex Pharmaceuticals. When does the fiscal year end for Vertex Pharmaceuticals?
Vertex Pharmaceuticals's fiscal year ends in December. Where is Vertex Pharmaceuticals based?
Vertex Pharmaceuticals's address is: 50 Northern Avenue, Boston, MA, United States, 02210 What is Vertex Pharmaceuticals's ISIN number?
Vertex Pharmaceuticals's international securities identification number is: US92532F1003 What is Vertex Pharmaceuticals's CUSIP number?
Vertex Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 92532F100

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.